Friday, March 29, 2019

Dow futures rise after Mueller finds Trump campaign did not conspire with Russia

Stock futures rose on Sunday night after special counsel Robert Mueller's long-awaited investigation did not find enough evidence that President Donald Trump 's 2016 campaign colluded with Russia, according to Attorney General William Barr.

Dow Jones Industrial Average futures traded 13 points higher, implying a gain of 54 points at Monday's open. The futures pared their gains after an initial pop at the open of trading. The summary of Mueller's findings comes amid worries about the global economy which hit stocks on Friday.

In a letter to top lawmakers, Barr wrote:

"The Special Counsel's investigation did not find that the Trump campaign or anyone associated with it conspired or coordinated with Russia in its efforts to influence the 2016 U.S. presidential election."

The White House also said the results are a "total and complete exoneration of the President of the United States."

Mueller's investigation had been a lingering concern for investors as it could have hindered Trump's efforts to further cut taxes and further ease regulations on corporations. The news removes a worry for Wall Street and can help the administration focus on more pressing issues for the market, such as striking a trade deal with China or even working with Democrats on an infrastructure plan.

"This cloud has now dissipated and this should allow markets to breathe a sigh of relief," said Jeff Kilburg, CEO of KKM Financial. "This could be a real positive for the market if it allows Trump to focus on getting the Chinese trade deal concluded."

The investigation nagged the Trump administration for nearly two years. It led to the indictment and arrest of several Trump's operatives, including ex-campaign manager Paul Manafort. Manafort was sentenced to 47 months in jail for fraud earlier this month.

Investors across the world worried the probe could also bring down Trump himself by potentially leading to his impeachment. Now, Wall Street can remove one block from the proverbial wall of worry and eye the ongoing U.S.-China trade talks.

"It's been like an aching joint," said Art Hogan, chief market strategist at National Securities. "It's always been that one market catalyst that has always been right around the corner."

"We may well have removed a nagging concern, but the current concerns like the China trade war and overseas grief that outweighs that. The disaster du jour was PMI and the global economy," said Hogan.

China and the U.S. are expected to strike a deal sometime in April. Sentiment around the negotiations improved this year to help lift stocks to within striking distance of their record highs set last year. White House press secretary Sarah Huckabee Sanders said Saturday that Treasury Secretary Steven Mnuchin and U.S. Trade Representative Robert Lighthizer were headed to Beijing for further talks on Thursday. Trade worries plagued investors for most of last year as they worried a prolonged trade war between the world's largest economies could hinder corporate profits.

Economic fears

"The fact that these tariffs may not be going away is having a negative multiplier effect on the global economy. There's a massive GDP destruction going on," said Larry McDonald, founder of The Bear Traps Report. "We will rally on [the Mueller report] but everything that took us down last week will keep rearing its ugly head again."

Equities fell sharply on Friday as an inverted yield curve stoked fears that an economic recession is on the horizon. Disappointing economic data released Friday out of Europe, coupled with a downgraded economic outlook from the Federal Reserve, added to those concerns.

The spread between the 3-month Treasury bill and the 10-year note went negative on Friday for the first time in more than a decade. Investors consider this to be a signal that a recession may be coming soon.

The futures' move higher on Sunday became more muted after the initial pop as the optimism on the Mueller probe faded and worries over the global economy lingered.

"I think the market was going to bounce back anyway and this gives it a little extra oomph," said Stephen Weiss, founder of Short Hills Capital Partners. "But overall the investigation rarely was a big concern for investors. If there is a big pop on this, you can likely fade it."

The S&P 500 is up nearly 31 percent since Trump was elected in 2016. One key catalyst for the move higher in that time is a massive corporate tax cut signed by Trump in late 2017.

"My instincts are that, at least at first pass, it seems to be relatively favorable," said Nathan Sheets, chief economist at PGIM Fixed Income, referring to the Mueller investigation ending. "Where all of this really connects to markets and markets outlook is implications for tax policy going forward. The sense has been if Trump is damaged, the tax cuts that were put in place could be reversed or — given the rhetoric we're hearing — taxes could even be increased."

—CNBC's Tom Franck contributed to this report.

Subscribe to CNBC on YouTube.

Saturday, March 23, 2019

Abeona Therapeutics (ABEO) Trading 9.2% Higher

Abeona Therapeutics Inc (NASDAQ:ABEO) shares traded up 9.2% during mid-day trading on Friday . The company traded as high as $8.14 and last traded at $8.10. 657,079 shares were traded during mid-day trading, an increase of 65% from the average session volume of 399,426 shares. The stock had previously closed at $7.42.

A number of research analysts have issued reports on the company. ValuEngine upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, March 5th. HC Wainwright restated a “buy” rating and issued a $30.00 price objective on shares of Abeona Therapeutics in a research note on Thursday, February 21st. BidaskClub downgraded Abeona Therapeutics from a “sell” rating to a “strong sell” rating in a research note on Tuesday, February 12th. Zacks Investment Research upgraded Abeona Therapeutics from a “sell” rating to a “hold” rating in a research note on Wednesday, February 6th. Finally, Mizuho restated a “buy” rating and issued a $17.00 price objective on shares of Abeona Therapeutics in a research note on Monday, December 10th. One research analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company’s stock. The company has an average rating of “Buy” and an average price target of $26.88.

Get Abeona Therapeutics alerts:

The company has a market capitalization of $355.74 million, a price-to-earnings ratio of -12.27 and a beta of 1.93.

Hedge funds have recently bought and sold shares of the company. BlackRock Inc. grew its stake in shares of Abeona Therapeutics by 1.6% during the 3rd quarter. BlackRock Inc. now owns 2,220,116 shares of the biopharmaceutical company’s stock worth $28,418,000 after acquiring an additional 35,610 shares during the period. Sphera Funds Management LTD. grew its stake in shares of Abeona Therapeutics by 51.0% during the 3rd quarter. Sphera Funds Management LTD. now owns 336,939 shares of the biopharmaceutical company’s stock worth $4,313,000 after acquiring an additional 113,767 shares during the period. Northern Trust Corp grew its stake in shares of Abeona Therapeutics by 28.2% during the 2nd quarter. Northern Trust Corp now owns 390,342 shares of the biopharmaceutical company’s stock worth $6,246,000 after acquiring an additional 85,908 shares during the period. Trexquant Investment LP bought a new position in shares of Abeona Therapeutics during the 3rd quarter worth $163,000. Finally, Teachers Advisors LLC grew its stake in shares of Abeona Therapeutics by 75.6% during the 3rd quarter. Teachers Advisors LLC now owns 98,192 shares of the biopharmaceutical company’s stock worth $1,257,000 after acquiring an additional 42,261 shares during the period. Institutional investors own 67.93% of the company’s stock.

TRADEMARK VIOLATION WARNING: This story was originally posted by Ticker Report and is the sole property of of Ticker Report. If you are reading this story on another website, it was illegally copied and reposted in violation of US and international copyright and trademark laws. The original version of this story can be read at https://www.tickerreport.com/banking-finance/4224632/abeona-therapeutics-abeo-trading-9-2-higher.html.

Abeona Therapeutics Company Profile (NASDAQ:ABEO)

Abeona Therapeutics Inc, a clinical-stage biopharmaceutical company, focuses on developing and delivering gene therapy products for severe and life-threatening rare diseases. The company's lead programs are EB-101 (gene-corrected skin grafts) for recessive dystrophic epidermolysis bullosa (RDEB); ABO-102, which are AAV based gene therapies for Sanfilippo syndrome type A; and ABO-101, an adeno-associated virus (AAV) based gene therapies for Sanfilippo syndrome type B.

Featured Story: What is Put Option Volume?

Thursday, March 21, 2019

Soleno Therapeutics News: Why SLNO Stock Is Skyrocketing Today

Soleno Therapeutics (NASDAQ:SLNO) had a Friday to remember as the biopharmaceutical company made some headway in a successful clinical trial of a treatment for a genetic disorder.

Soleno TherapeuticsSoleno Therapeutics Source: Flickr

The Redwood City, Calif.-based business announced that its Phase 3 trial of a tablet designed for patients afflicted with Prader-Willi syndrome (PWS) showed some improvement. The Data Safety Monitoring Board (DSMB) is recommending that the trial, which is operating under the moniker DESTINY PWS, for a diazoxide choline controlled-release tablet move forward as is.

Soleno Therapeutics is helping to ameliorate PWS patients, which is an illness that is mostly known for the symptom hyperphagia. This symptom makes those with the condition feel like they are always hungry. PWS can also lead patients to experience behavioral issues, including cognitive disabilities, lower-than-average muscle tone, an excess in body fat and incomplete sexual development.

“We are delighted with the DSMB’s positive recommendation to continue the Phase 3 trial as planned as it further supports DCCR’s safety profile,” Dr. Anish Bhatnagar, Soleno CEO , said in a statement. “We are continuing to enroll patients with 14 sites activated in DESTINY PWS.”

Dr. Bhatnagar also announced that patients will continue their treatment into C602, which is a nine-month study for patients who are a part of DESTINY PWS.

SLNO stock is skyrocketing about 213% on Friday following the news, which has the potential to improve the quality of hundreds of thousands of people. Roughly one in every 12,000 to 15,000 people is afflicted with PWS

Compare Brokers

Monday, March 18, 2019

Here's Why the Price of Gold Will Keep Going Up in 2019

This site uses Akismet to reduce spam. Learn how your comment data is processed.

Peter KrauthPeter Krauth

Bulls can stop worrying about the price of gold falling anytime soon.

I've been telling you for a while that a pullback was not only normal, but healthy. Now that the data is in, I'm going to show you why.

Gold prices just notched a huge gain over a short six-month period, blasting 14% higher between August and mid-February.

That's big. And if the gold price had continued to power any higher, its correction could have been worse.

So chalk it up to normal bull action of three steps forward and one step back as gold continues to climb its golden staircase.

Although the price of gold has dropped by about $60 from its recent peak, we may have already seen the worst.

The Fed's renewed dovish stance has lower real rates back as a driving factor for higher 2019 gold prices.

And consider too that, seasonally, gold tends to bottom around mid-March then climb through until end of May.

Gold has already printed a solid bounce back to $1,310 in just the last few days, strongly suggesting its correction has run its course.

With all this in mind, there are big things ahead for the price of gold in 2019…

Why the Gold Price Is Bouncing Back

Over the past three weeks, gold has come to terms with its strong gains between August and February, with the metal's price peaking on Feb. 20 at $1,346.

From the August low of $1,175, that produced a striking gain of $171, or 14.6%.

Since that February peak, gold has dropped back by about $60 to $1,286, giving up a total of 4.5%.

This correction in the gold price has been an almost perfect negative correlation with the U.S. Dollar Index (DXY), with about a five-day delay.

Looking at the action in the dollar, we can see that the DXY bottomed a few days after gold's February peak, and may have peaked just after gold's recent low.

But even as gold has corrected, its recent price action suggests that correction may have already hit a low.

The most recent CFTC Commitments of Traders report for the week ending March 5 shows that the net long position in gold futures dropped some 62%.

And despite such sudden, strong selling pressure, gold has held up well.

So far, gold's March 7 low has held above its Jan. 24 low, providing for a bullish higher low pattern.

It's still a bit early, but I believe we've seen the bottom of this gold correction.

What's more, if you consider the seasonal patterns of gold's behavior, we could be in a sweet spot right now.

Looking at gold's bull years since 2001, it typically bottoms in mid-March, then starts on a spring rally through until the end of May. In the chart below, you see the "high lows" circled immediately before a rally begins. This pattern should continue into 2019.

I think this potential rally has the ability to push gold above its February high near $1,340 by then. If gold can close above that level, then its previous high of $1,350 (last April) will lie within close reach.

Stronger Indicators for the Price of Gold in April

As I've said in previous updates, the dollar's direction is anything but clear at this point.

The DXY remains above its 50-day moving average, and both the relative strength index and moving average convergence divergence have been trending higher since early January.

As I've noted before, this doesn't seem to have gotten in gold's way, as gold prices have continued to rally in the face of a stronger dollar. That has been a bullish omen for gold in the past.

With the gold price back above its 50-day moving average, it's possible that $1,300 will now become a new support level.

If indeed the gold correction is over, it will have been relatively short, barely lasting three weeks.

Looking at gold stocks, we can see that even as gold was languishing around $1,285 between March 4 and March 7, they were attempting to push higher.

The VanEck Vectors Gold Miners ETF (NYSEArca: GDX) was trying to break higher each of those days, except for March 6, suggesting at the time that we could be witnessing a near-term bottom in gold, and that its next move would be higher.

Billions Are Now in Play: Millions of Americans could collect "Federal Rent Checks" – to learn how to claim your portion of an $11.1 billion money pool using this backdoor investment, click here now…

As it turns out, when we look at the gold stocks to gold ratio, it tells us that gold stocks held up better than gold through the correction and bounced back faster. In fact, gold stocks rose three times as much as gold since the metal started rallying late last week.

This kind of outperformance by gold equities may be foreshadowing more strength both in gold and gold stocks over the next few months.

So gold's taken a well-deserved break after rallying almost nonstop between August and February, and its technical price action is encouraging.

But on a fundamental basis, there are positive signs that gold is set to continue climbing higher this year. Here's how high the gold price is set to rise in 2019 – and a selection of the best investments for you to capitalize on it…

The Best Gold Funds for Your Money

Join the conversation. Click here to jump to comments…

Peter KrauthPeter Krauth

About the Author

Browse Peter's articles | View Peter's research services

Peter Krauth is the Resource Specialist for Money Map Press and has contributed some of the most popular and highly regarded investing articles on Money Morning. Peter is headquartered in resource-rich Canada, but he travels around the world to dig up the very best profit opportunity, whether it's in gold, silver, oil, coal, or even potash.

… Read full bio

Friday, March 15, 2019

Top Dividend Stocks To Buy For 2019

tags:CR,FFNW,SCG,PH,

This isn't my first relationship with Royal Bancshares of Pennsylvania (NASDAQ:RBPAA). A decade or so ago, I bought shares in this regional bank when it paid a 4% dividend and churned out steady, if not spectacular earnings. For a number of years, I was content to toss my dividends back to Royal in return for more shares. My share count grew as did my comfort level with this cozy little investment. Well, the line between contentment and complacency is a fine one that's easily crossed and once it is, things can become shall we say, interesting, if not downright dangerous. Without even realizing it, I had traversed that line and was about to pay the price.

I had warnings in 2006 and 2007 but if contentment is that warm glass of milk before bedtime, then complacency is a narcotic that no one, much less an investor, should ever ingest. By the time I finally came to my senses it was 2008, and we all know what happened in that wretched year; I sold my shares at a loss.

For the next couple of years, I busied myself with pursuits more rewarding than stock investing. You know, things like sorting my sock drawer, cleaning the garage, mowing the lawn and washing the car. As enthralling as these endeavors were, I couldn't get Royal Bancshares out of my mind. The bank was like a favorite child to me; a child that had gone wrong. I decided to keep informed on this small regional bank to see where the drama might lead me. And this, dear reader, is where my sob story ends and the real story begins.

Top Dividend Stocks To Buy For 2019: CRB Futures Index(CR)

Advisors' Opinion:
  • [By Max Byerly]

    Get a free copy of the Zacks research report on Crane (CR)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Shares of Crew Energy (TSE:CR) have been given a consensus recommendation of “Buy” by the eleven research firms that are presently covering the company, Marketbeat reports. One analyst has rated the stock with a hold rating and two have assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is C$3.37.

  • [By Stephan Byrd]

    Crew Energy (TSE:CR) insider James A. Taylor acquired 5,000 shares of the stock in a transaction that occurred on Monday, June 18th. The stock was acquired at an average cost of C$2.04 per share, for a total transaction of C$10,200.00.

  • [By Shane Hupp]

    BlackRock Inc. grew its stake in Crane Co. (NYSE:CR) by 2.2% during the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 4,303,084 shares of the conglomerate’s stock after acquiring an additional 93,264 shares during the period. BlackRock Inc. owned 7.21% of Crane worth $399,069,000 at the end of the most recent reporting period.

  • [By Ethan Ryder]

    Crew Energy (TSE:CR) had its price objective lowered by equities research analysts at Canaccord Genuity from C$4.50 to C$4.00 in a report issued on Tuesday. Canaccord Genuity’s price objective indicates a potential upside of 101.01% from the stock’s previous close.

  • [By Logan Wallace]

    Crew Energy Inc (TSE:CR) has received a consensus rating of “Buy” from the ten analysts that are presently covering the company, MarketBeat reports. One analyst has rated the stock with a hold recommendation and two have given a buy recommendation to the company. The average 1-year price objective among analysts that have issued a report on the stock in the last year is C$1.89.

Top Dividend Stocks To Buy For 2019: First Financial Northwest Inc.(FFNW)

Advisors' Opinion:
  • [By Max Byerly]

    First Financial Northwest (NASDAQ:FFNW) will be announcing its earnings results on Tuesday, July 24th. Analysts expect the company to announce earnings of $0.26 per share for the quarter.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on First Financial Northwest (FFNW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Get a free copy of the Zacks research report on First Financial Northwest (FFNW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Logan Wallace]

    Get a free copy of the Zacks research report on First Financial Northwest (FFNW)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Top Dividend Stocks To Buy For 2019: Scana Corporation(SCG)

Advisors' Opinion:
  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on SCANA (SCG)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Chris Lange]

    The stock posting the largest daily percentage gain in the S&P 500 ahead of the close Wednesday was SCANA Corp. (NYSE: SCG) which rose over 22% to $47.71. The stock's 52-week range is $37.10 to $73.81. Volume was about 19 million compared to its average volume of 2 million.

  • [By Reuben Gregg Brewer]

    If you're like me, you love dividend stocks, particularly ones with high yields. However, you have to look past the yield when you weigh an investment, because all dividends are not created equal. Today, for example, utility SCANA Corp. (NYSE:SCG) and bookseller Barnes & Noble Inc. (NYSE:BKS) both offer hefty payouts, but neither should be added to your portfolio.

  • [By Chris Lange]

    The S&P 500 stock posting the largest daily percentage loss ahead of the close Tuesday was SCANA Corp. (NYSE: SCG) which traded down roughly 5% at $41.13. The stock's 52-week range is $37.10 to $71.28. Volume was 3.5 million, compared with the daily average of 3 million shares.

  • [By Shane Hupp]

    Teacher Retirement System of Texas cut its stake in shares of SCANA Co. (NYSE:SCG) by 8.3% in the second quarter, HoldingsChannel.com reports. The fund owned 27,484 shares of the utilities provider’s stock after selling 2,503 shares during the period. Teacher Retirement System of Texas’ holdings in SCANA were worth $1,059,000 as of its most recent filing with the Securities and Exchange Commission.

  • [By Reuben Gregg Brewer]

    While all of this is going on, Dominion has also announced plans to buy financially struggling peer SCANA Corp. (NYSE:SCG). This utility got into trouble when it canceled a nuclear construction project midstream after its contractor declared bankruptcy. Regulators, customers, and politicians have been less than pleased, with demands for rate and dividend cuts (a dividend cut was just announced).

Top Dividend Stocks To Buy For 2019: S&P Smallcap 600(PH)

Advisors' Opinion:
  • [By Ethan Ryder]

    Parker-Hannifin (NYSE:PH) had its price target boosted by Wells Fargo & Co from $185.00 to $193.00 in a research note released on Thursday, The Fly reports. Wells Fargo & Co currently has a market perform rating on the industrial products company’s stock.

  • [By Logan Wallace]

    Investment analysts at Barclays started coverage on shares of Parker-Hannifin (NYSE:PH) in a report issued on Thursday, MarketBeat reports. The firm set an “overweight” rating and a $200.00 price target on the industrial products company’s stock. Barclays’ price target indicates a potential upside of 12.54% from the stock’s current price.

  • [By Shane Hupp]

    ClariVest Asset Management LLC reduced its stake in shares of Parker Hannifin (NYSE:PH) by 3.0% during the 1st quarter, according to its most recent filing with the SEC. The firm owned 122,268 shares of the industrial products company’s stock after selling 3,773 shares during the period. ClariVest Asset Management LLC owned approximately 0.09% of Parker Hannifin worth $20,913,000 at the end of the most recent quarter.

  • [By Shane Hupp]

    Barings LLC decreased its holdings in Parker Hannifin (NYSE:PH) by 36.4% in the first quarter, HoldingsChannel reports. The firm owned 26,064 shares of the industrial products company’s stock after selling 14,937 shares during the period. Barings LLC’s holdings in Parker Hannifin were worth $4,458,000 as of its most recent SEC filing.

  • [By Logan Wallace]

    Ardevora Asset Management LLP reduced its stake in shares of Parker Hannifin (NYSE:PH) by 0.5% in the first quarter, HoldingsChannel.com reports. The fund owned 154,400 shares of the industrial products company’s stock after selling 800 shares during the quarter. Ardevora Asset Management LLP’s holdings in Parker Hannifin were worth $26,407,000 as of its most recent filing with the Securities & Exchange Commission.

  • [By Ethan Ryder]

    Get a free copy of the Zacks research report on Parker-Hannifin (PH)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

Thursday, March 14, 2019

Why Shares of Vera Bradley Surged Today

What happened

Shares of Vera Bradley (NASDAQ:VRA) soared on Wednesday following a fourth-quarter report that beat expectations. The fashion specialist's revenue and earnings came in ahead of analyst estimates, and its full-year guidance was better than expected. As of 11:55 a.m. EDT, the stock was up about 19.9%.

So what

Vera Bradley reported fourth-quarter revenue of $118.2 million, down 10.5% year over year but nearly $2 million above the average analyst estimate. The company's guidance had called for revenue between $114 million and $119 million.

A Vera Bradley bag.

Image source: Vera Bradley.

Comparable-store sales dropped by 2.4% in the quarter, while e-commerce sales plunged 27.4%. Overall comparable sales were down 11.2%. The company closed 10 full-line stores and opened six factory outlet stores over the past year, which hurt sales. The prior-year period also featured an extra week that produced $3 million of additional revenue last year.

Earnings per share came in at $0.25, up from $0.24 in the prior-year period and $0.02 better than analysts were expecting. Lower revenue was offset by a reduction in operating expenses, a slightly higher gross margin, and a substantially lower tax rate.

Now what

Vera Bradley expects to return to growth in the first quarter. The company forecast revenue between $86 million and $91 million, up from $86.6 million in the prior-year period.

For the full year, Vera Bradley expects revenue of $420 million to $440 million, up from $416.1 million in fiscal 2019. EPS is forecast to rise to a range of $0.64 to $0.74, up from $0.59 last year. Analysts were expecting revenue of $407 million and EPS of $0.63.

With Vera Bradley calling for a return to growth this year, the worst may finally be over for the struggling fashion company.

Wednesday, March 13, 2019

Eli Lilly’s Latest Move Proves the American Healthcare System Is Broken

Eli Lilly (NYSE:LLY) announced March 4 that it was introducing a half-price generic version of Humalog, the company’s insulin injection medication. Not surprisingly, LLY stock barely budged on the news, losing 1.4% on the day.

Eli Lilly stock LLY stockEli Lilly stock LLY stockSource: Paul Sableman via Flickr

I don’t own LLY stock. I’ve never contemplated holding it, and this latest move by the company ensures that I will never own Eli Lilly stock. Here’s why.

A Purely Financial Reason

In 2018, Humalog generated $3.0 billion for Eli Lilly, 5% higher than a year earlier. Assuming Humalog’s gross margin is 73.8% (I’m using the company’s overall gross margin; it’s likely higher), Eli Lilly had $2.2 billion in gross profits from this single drug.

Except for Trulicity, the company’s bestselling diabetes drug, Humalog is the company’s second-largest revenue and profit generator.

In 2016, the Washington Post found that Eli Lilly increased the price of Humalog from $21 a bottle in 1996, to $255 two decades later, a 700% increase adjusting for inflation.

I wish I could get a 700% increase in my annual earnings over the next 20 years, but that’s unlikely to happen.

Why would the company introduce a half-price version of a drug when it’s a cash cow?

“While this change is a step in the right direction, all of us in the health care community must do more to fix the problem of high out-of-pocket costs for Americans living with chronic conditions,” CEO David Ricks said in the company’s press release. “We hope our announcement is a catalyst for positive change across the U.S. health care system.”

That’s the Official Explanation

The truth is far murkier.

“By offering a generic version, it allows Lilly to fend off the criticisms,” said Andrew Ching, a professor at Johns Hopkins University’s Carey Business School. “By keeping the branded version, it allows them to keep charging a high price to the segment of consumers who are willing to pay more.”

Why on god’s green earth would you pay more if you didn’t have to? On the surface, it’s good news for patients.

“Lilly isn’t the first drug maker to cut list prices on a best-seller, but it is the first to do so for a product as widely used as Humalog, and the move could have ramifications for the entire market,” stated Max Nisen of the Peoria Star. “For patients, it’s good news.”

But is it?


Compare Brokers

Eli Lilly Falls Way Short of the Target

Excellent news would be the company ending full-priced Humalog sales, replaced permanently by Insulin Lispro, the name of the new generic version, but that’s not going to happen.

The company is going to continue to herd as many people as possible into the more expensive version, which is good news if you own LLY stock, but terrible news if you’re hoping this is the start of healthcare reckoning day.

It’s not.

The price of a vial of Humalog is close to $300. Cut that in half, and we’re still talking about pulling one Benjamin Franklin and five Alexander Hamilton’s out of your pocket.

Here’s a tweet from Senator Dick Durbin:

“Eli Lilly is trying to save face by lowering prices for some to $140 for a vial of insulin that’s available in Canada for as little as $38. It’s time for Big Pharma to stop the #PharmaFleece.”

If Durbin’s tweet doesn’t highlight just how broken America’s healthcare system is, I don’t know what will.

The Bottom Line on LLY Stock

This move by Eli Lilly is an act of desperation to save its gravy train. Do not for one minute think this is anything more than a PR stunt meant to appease the federal government so it won’t introduce legislation forcing lower drug prices.

“If drug companies want to be part of the solution, rather than part of the problem, they should lead the way in simplifying our healthcare system so that patients can obtain affordable medicine that still provides manufacturers with a reasonable return on their investment,” wrote Los Angeles Times columnist and Humalog user, David Lazarus.

As someone who lives in Canada, I am so thankful that I don’t have to negotiate my way through the American healthcare system. I’m not saying the Canadian system is perfect, far from it, but this move by Eli Lilly reeks of a payoff.

The system is broken. And now, so is LLY stock.

As of this writing Will Ashworth did not hold a position in any of the aforementioned

Tuesday, March 12, 2019

Odonate Therapeutics Inc (ODT) CEO Kevin C Tang Bought $2.6 million of Shares

CEO of Odonate Therapeutics Inc (NASDAQ:ODT) Kevin C Tang bought 140,000 shares of ODT on 03/08/2019 at an average price of $18.26 a share. The total cost of this purchase was $2.6 million.

Odonate Therapeutics Inc is a pharmaceutical company which is engaged in the development of therapeutics which improves and extend the lives of patients with cancer. It is developing tesetaxel an chemotherapy agent used in the treatment of cancer. Odonate Therapeutics Inc has a market cap of $517.410 million; its shares were traded at around $19.34 .

CEO Recent Trades:

CEO, 10% Owner Kevin C Tang bought 140,000 shares of ODT stock on 03/08/2019 at the average price of $18.26. The price of the stock has increased by 5.91% since.

Directors and Officers Recent Trades:

Director Jeff L Vacirca bought 3,000 shares of ODT stock on 03/04/2019 at the average price of $17. The price of the stock has increased by 13.76% since.

For the complete insider trading history of ODT, click here

.

Monday, March 11, 2019

SpaceX and ULA Get Launch Contracts. ULA Wins Almost 50% More Money

[W]ith each passing day, I'm more and more convinced that Boeing and Lockheed's ULA joint venture is doomed to fail. Ever since the U.S. Air Force certified SpaceX's Falcon 9 medium lift rocket to carry payloads four years ago, Falcon 9 has won every bid for such missions in which it competed against Atlas V rockets bid by ULA. -- Me, eight months ago

But that was then, and this is now.

Today, SpaceX continues to charge the U.S. government significantly less (than United Launch Alliance does) for launch services. However, a pair of recent contracts totaling $739 million in value demonstrates that the U.S. government is in fact willing to pay ULA more than SpaceX for the same work -- at least sometimes. But perhaps even more important to the future prospects of ULA and its co-owners Boeing and Lockheed Martin (NYSE:LMT), ULA's rockets are getting cheaper and moving closer to price parity with SpaceX's.

Atlas V rocket launch from Cape Canaveral.

The Pentagon just ordered up three more ULA Atlas launches and three Falcons from SpaceX. Image source: Getty Images.

$739 million in space contracts

Allow me to explain.

Last month, the U.S. Air Force announced the award of six launch contracts to be divided between SpaceX and ULA. SpaceX will launch the missions designated NROL-87, NROL-85, and AFSPC-44 for a total cost of $297 million ($99 million per launch). ULA will be responsible for Silent Barker, aka NROL-107, SBIRS GEO-5, and SBIRS GEO-6. ULA will be paid $441.8 million for its three launches -- $147.3 million apiece.

And that is clearly the headline here. With $739 million up for grabs, SpaceX and ULA are being given basically the same work to do -- but ULA will be paid 49% more to do it. Now, the Air Force would probably argue that this is fair and certainly within its discretion. After all, at the time bids were solicited for these contracts last year, Space and Missile Systems Center commander Lt. Gen. John Thompson explained that awards would be based on "a trade-off between past performance, performance and schedule sub-factors, and price."

SpaceX's lower prices being the last factor in that list, USAF apparently viewed them as being of less importance than ULA's longer record of reliability and (slightly) better payload capacity to geosynchronous transfer orbit (in some configurations). I also wouldn't discount the possibility that the Air Force put its thumb on the scales and awarded half its launch business to ULA in an effort to ensure there remain at least two horses in this race -- so that the government can continue to play one against the other to extract better prices from each.

Giving credit where it's due

But let's also give credit where credit is due: The Air Force's plan is working.

Even if ULA is still charging a lot more than SpaceX does, and for essentially the same work -- and even if the government is still voluntarily paying that premium -- ULA CEO Tory Bruno has made significant progress in lowering the cost of the launch services it sells to the government so as to better compete with SpaceX. (It's also worth noting that this hasn't yet done any obvious damage to ULA's profit margins. In fact, ULA co-owner Lockheed Martin, which breaks out results for its space business separately, showed a small uptick in space profit margins in 2018, according to data from S&P Global Market Intelligence.)

Just two years ago, in surveying the prices charged by various launch providers for their services, I noted that according to ULA's published figures, one of ULA's cheaper Atlas V missions was still expected to cost $164 million, and "launch costs across its entire fleet average $225 million."

At an average launch cost of $147.3 million, last month's contract awards show that at the very least, ULA seems to have succeeded in shaving 10% off its launch cost -- and potentially as much as 35%. (Because ULA doesn't publish a detailed price schedule, we don't know precisely how much it has charged for past launches using the Atlas 5-421 configuration that it will be using for the two SBIRS launches. This makes it hard to do an exact apples-to-apples comparison between launch prices then versus launch prices now.)

But we do know that ULA is offering at least some price improvement and that these better prices are being offered on not just any missions but on missions so complex and secretive that they're only known by code name (e.g., Silent Barker, believed to be a "collaborative [intelligence] acquisition" program run by the National Reconnaissance Office and U.S. Air Force). Such missions almost certainly involve more government red tape and higher expenditures to ensure mission success than simply lofting a commercial TV satellite into orbit, for example.

Yet ULA has managed to cut its prices regardless -- and thanks to competition from SpaceX, the U.S. government has managed to make ULA cut its prices in order to win contracts.

This still doesn't seem exactly fair to SpaceX, but it's a win-win-win for ULA, the USAF, and taxpayers.

Sunday, March 10, 2019

Arcturus Therapeutics (ARCT) Stock Rating Upgraded by Zacks Investment Research

Arcturus Therapeutics (NASDAQ:ARCT) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a research note issued to investors on Thursday.

According to Zacks, “Arcturus Therapeutics Ltd. is a preclinical-stage biopharmaceutical company. It focuses on the discovery, development and commercialization of RNA medicines using proprietary lipid-mediated delivery system LUNAR(TM) and UNA Oligomer chemistry technologies. Arcturus Therapeutics Ltd, formerly known as Alcobra Ltd, is based in San Diego, CA. “

Get Arcturus Therapeutics alerts:

Several other research analysts have also recently weighed in on ARCT. Roth Capital restated a “buy” rating on shares of Arcturus Therapeutics in a research note on Wednesday, February 20th. Laidlaw initiated coverage on Arcturus Therapeutics in a report on Tuesday, February 19th. They issued a “buy” rating for the company. Finally, ValuEngine lowered Arcturus Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 21st. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Arcturus Therapeutics has a consensus rating of “Buy” and an average target price of $5.25.

Shares of ARCT stock traded down $0.13 during trading hours on Thursday, reaching $4.60. The company’s stock had a trading volume of 1,319 shares, compared to its average volume of 38,135. The firm has a market cap of $48.78 million, a P/E ratio of -1.30 and a beta of 2.14. Arcturus Therapeutics has a one year low of $4.11 and a one year high of $10.00.

A number of large investors have recently added to or reduced their stakes in the business. JPMorgan Chase & Co. boosted its stake in shares of Arcturus Therapeutics by 91.7% in the third quarter. JPMorgan Chase & Co. now owns 16,744 shares of the biotechnology company’s stock worth $148,000 after acquiring an additional 8,008 shares during the period. BlackRock Inc. purchased a new stake in shares of Arcturus Therapeutics in the second quarter worth about $169,000. Worth Venture Partners LLC purchased a new stake in shares of Arcturus Therapeutics in the third quarter worth about $290,000. Finally, ARK Investment Management LLC lifted its position in shares of Arcturus Therapeutics by 45.0% in the third quarter. ARK Investment Management LLC now owns 773,772 shares of the biotechnology company’s stock worth $6,840,000 after buying an additional 239,999 shares in the last quarter. 10.29% of the stock is owned by institutional investors and hedge funds.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Ltd., an RNA medicines company, develops nucleic acid medicines to treat diseases with unmet medical needs. Its RNA therapeutics platforms could be applied in various types of RNA medicines, including small interfering RNA, messenger RNA, replicon RNA, antisense RNA, microRNA, and gene editing therapeutics.

Featured Article: Return on Investment (ROI)

Get a free copy of the Zacks research report on Arcturus Therapeutics (ARCT)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Arcturus Therapeutics (NASDAQ:ARCT)

Saturday, March 9, 2019

City Holding (CHCO) Given Consensus Recommendation of “Buy” by Brokerages

City Holding (NASDAQ:CHCO) has earned an average rating of “Buy” from the six brokerages that are presently covering the company, MarketBeat.com reports. Four research analysts have rated the stock with a hold recommendation, one has assigned a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month price objective among brokerages that have covered the stock in the last year is $80.00.

A number of analysts have issued reports on the company. BidaskClub raised City from a “hold” rating to a “buy” rating in a report on Thursday, November 15th. Zacks Investment Research raised City from a “hold” rating to a “buy” rating and set a $86.00 price target for the company in a report on Friday, November 30th. Finally, Boenning Scattergood reaffirmed a “hold” rating on shares of City in a report on Thursday, January 24th.

Get City alerts:

In other news, CEO Charles R. Hageboeck sold 1,593 shares of the business’s stock in a transaction dated Thursday, February 28th. The stock was sold at an average price of $79.50, for a total value of $126,643.50. Following the completion of the sale, the chief executive officer now directly owns 57,121 shares of the company’s stock, valued at approximately $4,541,119.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Charles R. Hageboeck sold 4,154 shares of the business’s stock in a transaction dated Monday, February 25th. The shares were sold at an average price of $79.77, for a total value of $331,364.58. Following the completion of the sale, the chief executive officer now directly owns 60,405 shares of the company’s stock, valued at $4,818,506.85. The disclosure for this sale can be found here. Insiders have sold a total of 6,565 shares of company stock valued at $522,916 over the last ninety days. 3.83% of the stock is owned by company insiders.

Several institutional investors have recently bought and sold shares of CHCO. BlackRock Inc. lifted its holdings in shares of City by 6.3% in the 4th quarter. BlackRock Inc. now owns 2,359,912 shares of the bank’s stock valued at $159,507,000 after purchasing an additional 139,779 shares during the last quarter. Norges Bank purchased a new stake in shares of City in the 4th quarter valued at about $9,173,000. Walthausen & Co. LLC purchased a new stake in shares of City in the 3rd quarter valued at about $10,223,000. Macquarie Group Ltd. lifted its holdings in shares of City by 25.6% in the 3rd quarter. Macquarie Group Ltd. now owns 470,684 shares of the bank’s stock valued at $36,149,000 after purchasing an additional 95,894 shares during the last quarter. Finally, Vanguard Group Inc lifted its holdings in shares of City by 2.4% in the 3rd quarter. Vanguard Group Inc now owns 1,590,260 shares of the bank’s stock valued at $122,133,000 after purchasing an additional 36,829 shares during the last quarter. 69.65% of the stock is owned by institutional investors and hedge funds.

CHCO opened at $75.33 on Friday. City has a 12 month low of $65.32 and a 12 month high of $83.27. The firm has a market cap of $1.22 billion, a P/E ratio of 14.60, a P/E/G ratio of 1.87 and a beta of 0.70. The company has a quick ratio of 0.90, a current ratio of 0.87 and a debt-to-equity ratio of 0.01.

City (NASDAQ:CHCO) last announced its quarterly earnings results on Thursday, January 24th. The bank reported $1.35 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $1.24 by $0.11. The company had revenue of $51.14 million during the quarter, compared to the consensus estimate of $52.88 million. City had a return on equity of 15.23% and a net margin of 31.15%. As a group, research analysts forecast that City will post 5.33 EPS for the current fiscal year.

City Company Profile

City Holding Company operates as a holding company for City National Bank of West Virginia that provides various banking, trust and investment management, and other financial solutions in the United States. The company accepts various deposit products, such as checking, savings, and money market accounts, as well as certificates of deposit and individual retirement accounts.

Featured Story: What are different types of coverage ratios?

Friday, March 8, 2019

Travala.com One Day Trading Volume Reaches $5,808.00 (AVA)

Travala.com (CURRENCY:AVA) traded 1.4% lower against the U.S. dollar during the 24 hour period ending at 20:00 PM E.T. on March 6th. One Travala.com token can currently be purchased for approximately $0.10 or 0.00002573 BTC on major cryptocurrency exchanges. In the last week, Travala.com has traded down 2.7% against the U.S. dollar. Travala.com has a market capitalization of $3.79 million and $5,808.00 worth of Travala.com was traded on exchanges in the last day.

Here is how other cryptocurrencies have performed in the last day:

Get Travala.com alerts: XRP (XRP) traded 1.1% higher against the dollar and now trades at $0.32 or 0.00008109 BTC. Binance Coin (BNB) traded 8.2% higher against the dollar and now trades at $14.61 or 0.00373401 BTC. Tether (USDT) traded down 0.2% against the dollar and now trades at $1.01 or 0.00025819 BTC. Stellar (XLM) traded up 0.3% against the dollar and now trades at $0.0859 or 0.00002195 BTC. TRON (TRX) traded 1% lower against the dollar and now trades at $0.0234 or 0.00000599 BTC. Bitcoin SV (BSV) traded 0% higher against the dollar and now trades at $66.89 or 0.01709612 BTC. NEO (NEO) traded up 0.6% against the dollar and now trades at $8.84 or 0.00225937 BTC. VeChain (VET) traded up 0.5% against the dollar and now trades at $0.0044 or 0.00000112 BTC. Basic Attention Token (BAT) traded 1.3% lower against the dollar and now trades at $0.17 or 0.00004449 BTC. TrueUSD (TUSD) traded down 0.1% against the dollar and now trades at $1.01 or 0.00025904 BTC.

Travala.com Token Profile

Travala.com launched on August 4th, 2017. Travala.com’s total supply is 61,571,086 tokens and its circulating supply is 37,603,443 tokens. The Reddit community for Travala.com is /r/Travala and the currency’s Github account can be viewed here. The official message board for Travala.com is medium.com/@travala. Travala.com’s official Twitter account is @Avalonplatform. Travala.com’s official website is www.travala.com.

Buying and Selling Travala.com

Travala.com can be traded on these cryptocurrency exchanges: Switcheo Network. It is usually not possible to purchase alternative cryptocurrencies such as Travala.com directly using US dollars. Investors seeking to trade Travala.com should first purchase Ethereum or Bitcoin using an exchange that deals in US dollars such as Gemini, Changelly or GDAX. Investors can then use their newly-acquired Ethereum or Bitcoin to purchase Travala.com using one of the aforementioned exchanges.

new TradingView.widget({ “height”: 400, “width”: 650, “symbol”: “AVAUSD”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Thursday, March 7, 2019

Care.com Inc (CRCM) Q4 2018 Earnings Conference Call Transcript

Logo of jester cap with thought bubble.

Image source: The Motley Fool.

Care.com Inc  (NYSE:CRCM)Q4 2018 Earnings Conference CallMarch 07, 2019, 8:00 a.m. ET

Contents: Prepared Remarks Questions and Answers Call Participants Prepared Remarks:

Operator

Greetings, and welcome to Care.com's Fourth Quarter and Full Year 2018 Conference Call. At this time, all participants are in a listen-only mode. A question-and-answer session will follow the formal presentation. (Operator Instructions) As a reminder, this conference is being recorded.

It is now my pleasure to turn the call over to, Mike Goss, Vice President of Finance for Care.com. Please go ahead, Mike.

Mike Goss -- Vice President of Finance

Thank you. Good morning, and welcome to Care.com's financial results call for the fourth quarter and full year ended December 29, 2018.

During the course of this conference call, we will discuss our business outlook and make other forward-looking statements within the meaning of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. These may include, among other things, projected financial results or operating metrics, anticipated business and marketing investments, as well as strategies and expected results of those investments and strategies, anticipated future products or services, anticipated market demand or opportunities for our products and services and other forward-looking topics.

Such statements are only predictions based on Management's current expectations. Actual results or events could differ materially from those predictions due to a number of risks and uncertainties, including those set forth in the press release we issued today, as well as those more fully described in our filings with the Securities and Exchange Commission.

In addition, any forward-looking statements represent our views only as of today and should not be relied upon as representing our views as of any subsequent date. While we may elect to update these forward-looking statements at some point in the future, we specifically disclaim any obligation to do so, even if our views change except as required by law. Therefore, you should not rely on these forward-looking statements, as representing our views, as of any date subsequent to today.

We will also be referring to non-GAAP measures on this call, including adjusted EBITDA, which we refer to as EBITDA throughout this presentation. This measure represents pre-tax net income from continuing operations which excludes the accretion of preferred stock dividends and issuance costs, as well as federal and state franchise taxes and other income expense net, depreciation and amortization, stock-based compensation, accretion of contingent consideration, merger and acquisition related costs and other unusual or non-significant adjustments such as impairment or restructuring charges.

We also refer to non-GAAP EPS, which excludes the accretion of preferred stock dividends, plus stock based compensation, accretion of contingent consideration, merger and acquisition related costs and other unusual or non-significant cap (ph) adjustments such as impairment, restructuring charges and the release of valuation allowance for deferred taxes due to projections of taxable income. These non-GAAP measures are not prepared in accordance with generally accepted accounting principles. Reconciliations to the most directly comparable GAAP financial measures are provided in the tables in the press release issued today, which is available on our IR website.

We will also be referring to profitability on this call. When we refer to profitability, we're referring to it on an adjusted EBITDA basis, unless otherwise noted.

Today's call is available via webcast and a telephone replay and will be available for one week following the conclusion of this call. To access the press release, supplemental and financial information or the webcast replay, please consult our IR website.

With that, let me turn the call over to Sheila Lirio Marcelo, Founder, Chairwoman and CEO of Care.com.

Sheila Lirio Marcelo -- Founder, Chairwoman & Chief Executive Officer

Thank you, Mike. Good morning, and thank you to everyone for joining us. We're very pleased with our strong finish to 2018. In the fourth quarter, our growth accelerated to 13% driven by accelerating momentum in our US Consumer business and Care@Work.

In US Consumer, product improvements in our mobile and desktop experiences drove improving conversion, which is leading to accelerating growth in end of period members and revenue. In Care@Work signature wins of larger clients like Starbucks and Best Buy, as announced in the press, fueled growth. We were able to generate solid leverage across our scalable business model and convert our net sales growth to meaningful EBITDA and cash generation.

As we start 2019, we are excited to continue growing both US Consumer and Care@Work with a goal of penetrating ever more of the $336 billion spent annually on care predominantly on child care and senior care. With our leading consumer and enterprise platforms that provide mass-market solutions for people at all income levels, we believe we play a critical role in building a scalable care infrastructure to address the future of work for both families and caregivers. We remain confident that the building blocks that we put in place in 2018 will enable us to accelerate growth in 2019.

In 2018, we continue to grow our business profitably, increasing the top line by 10% to $192.3 million, while delivering $32.2 million in EBITDA and expanding EBITDA margin by 340 basis points to 16.8%. This profitable growth was driven by strength in our US Consumer business and Care@Work, coupled with gains in operating leverage, particularly in sales and marketing. The ROI in our US Consumer business improved to 6.4x in 2018 from 4.7x in 2017. These efficiency gains and the overall profitability in our business flowed through to continued healthy cash generation. We added $25.8 million in cash and short-term investments in 2018, finishing the year with $127.5 million on our balance sheet.

I'll now briefly recap our progress in each business in 2018, and our strategic priorities for 2019. Starting with US matching, we saw end of period paying family growth of 12% for 2018 versus 2017. We achieved this growth, while improving our unit economics, driven by efficiency gains in our costs to acquire new members. While we did see a slight decline in average revenue per user or ARPU, which we anticipated based on the mix shift toward longer duration subscription, this was as expected more than offset by growth in length of paid time.

Moving on to total company sales and marketing, which as a percent of revenue was 31.5% for 2018, a 7 percentage point improvement versus 2017. Our continued leverage in sales and marketing was driven by decreasing US Consumer CAC through a combination of product investments, including ongoing mobile and unpaid channel optimization and overall paid marketing efficiency gain. CAC declined 25% from $97 in 2017 to $73 in 2018.

This CAC improvement and the related notable increase in ROI that I described earlier give us the flexibility to spend incrementally on sales and marketing in 2019, and to do so effectively on the back of the efficiency and conversion gains we've achieved. This incremental spending in 2019 will follow a few years in which sales and marketing spend came down versus prior, as we focused on reducing direct marketing spend, while improving mobile conversion and organic growth. And in the context of improving unit economics, we believe that our planned investments in direct marketing spend in 2019 will help us make progress relative to our long-term goals on both the top and bottom line. Michael will share his regular unit economics deep-dive shortly, and then he will provide guidance in the context of these planned investments.

The improvements in our unit economics are directly related to our continued progress with Care 3.0 which we kicked off in 2017. This includes continued optimization of our enrollment flows, improvements in our organic initiatives, namely in search engine optimization and our ongoing investments in content and our community experience, and driving more of our web users to download our mobile app now at 4.6 stars in the iOS store.

Our mobile app users have been matching faster and more often, and have shown to be more likely to reupgrade down the road, driving the future length of paid time. We've also introduced a separate provider app with meaningful increases in installs. After a multi-year investments in mobile transformation and now with a stronger foundation in our improved consumer platforms, all combined with our leading brand, we expect to drive further growth in our end of period members and thus US Consumer revenue by integrating recent child care product tuck-in acquisitions and investing more in our fastest growing vertical senior care.

Starting with our tuck-in acquisitions in child care. We believe combining our leading position in child care with a focus on offering higher frequency care solutions such as on-demand babysitting and after school activities will not only improve our conversion rates, but also expand our length of paid time flowing through to end of period member growth.

A quick note on after school, one of the largest segments within child care. In 2018, we acquired Galore now called Care.com Explore to help families find valuable after school activities for their children's academic and social development. With the integration of Care.com Explore, our goal is to help make it easier for families to find and schedule local activities, as a way of addressing daily needs beyond hiring nannies and babysitters. As the next step, we are pleased to announce another tuck-in acquisition that we believe will help us achieve our vision for a holistic after school offering, Figure8.

Through a mobile app designed to facilitate the management of the many moving parts in kids after school schedules, Figure8 makes communication and coordination easier with relatives, other families and caregivers. And we're excited to have the talented Figure8 team join the Care.com family. With a strong global foundation in our core US Consumer matching offering, we are excited to integrate these higher frequency care solutions to help further drive end of period member growth and US Consumer revenue.

Now moving on to senior care. The market for senior care is growing fast given positive demographic trends. According to AARP, 10,000 boomers a date turn 65. This trend is expected to continue into the 2030s. We believe we can efficiently drive both engagement and growth in this vertical. We see significant opportunity in senior care, in particular given the early marketing investments and product enhancements we made in 2017 and 2018.

Building on a more verticalized mobile enrollment flow and our learnings from our senior care specific test spending, we intend to continue our investment in senior care growth in 2019. Our unit economic improvements that I mentioned earlier are comparable between child care and senior care. These results give us confidence that our senior care investments can contribute to further end of period member growth. In summary, with our stronger US matching platform, improving unit economics and leading brand, we believe we are positioned well to drive further acceleration in US Consumer revenue growth acceleration in 2019.

Moving now to our Care@Work business, which continues to scale with 2018 revenue growth versus prior of 34%. And our innovative care work experience and exceptional service delivery are driving our high revenue renewal rate of 100% plus, we are pleased with this performance. Similar to our US Consumer matching business, our focus with Care@Work has been on expanding our reach to serve more families, especially those on the front line with ever shifting work schedules that make balancing work and care challenging. A recent study by Harvard Business School on The Caring Company found that employees across industries are expressing their growing need for care benefit, and that companies that help with their employees care needs can gain a competitive advantage. We are excited to continue to help companies' gain that advantage.

Our new clients that have large diverse employee pool such as Starbucks and Best Buy are an important part of our inclusive approach to meeting growing care needs by building out a care infrastructure to serve the mass market. We are pleased to announce the addition in Q4 of Meijer, one of the largest grocery chains in the Midwest with nearly 70,000 employees. The Meijer team noted to us that Care@Work aligns with one of their core values family. In Q4, we also added other new clients, including Western Union, Rosetta Stone (inaudible) Heidrick & Struggles and Cushman & Wakefield. And we had renewals from a range of industries including clients like AACOM, NVIDIA, West Virginia University, Pillsbury Winthrop and Houston Methodist. We are excited both about the overall momentum in our Care@Work business and about having innovative companies like these alongside us in our mission to help all families.

We're also planning strategic investments in 2019 to build on this momentum and drive further growth in Care@Work. For example, we will be making investments in both our direct sales team and in other channels to expand our reach. We are also planning improvements to the user interface, infrastructure investments and tested innovative offerings around affordable care solutions that are especially important for our largest new customers. We believe Care@Work have meaningful growth potential, and we expect that it will remain the fastest growing piece of our overall business in 2019.

As we scale both the B2B and B2C parts of our business, we are focused on operational excellence to ensure, we deliver an exceptional member and client experiences, investing in member care, safety and cyber security and overall service delivery enables us to continue to build trust in our leading brand. Across our consumer and enterprise services, we maintain best-in-class net promoter scores that contribute to growth.

In summary, we are continuing to deliver on our mission for our millions of families and caregivers, while driving consistent profitable growth. 2018 was a successful year for us, where we saw revenue growth acceleration in Q4 driven by US Consumer and Care@Work, and we expect to see continued top line momentum in 2019.

Before I turn the call over to Michael, I want to note that Laela Sturdy is stepping down from our Board this spring after three years of service. I want to thank her, for her many significant contribution and wish her well.

Now, I'll turn the call over to Michael before we open it up to questions.

Michael Echenberg -- Chief Financial Officer

Thank you, Sheila. First, I'll provide more color on our fourth quarter and full year 2018 results; and then, I'll share our outlook for the full year and first quarter of 2019.

I'll start with full year revenue, which grew 10% versus prior from $174.1 million in 2017, to $192.3 million in 2018 within our guidance range. Q4 revenue grew 13% from $44.2 million in Q4 of 2017 to $49.8 million in Q4 of 2018. This 13% represents acceleration relative to the 10.5% growth, we saw for Q3, '18 versus Q3, '17 and the 9% growth we saw for the first half of 2018 versus the first half of 2017.

Digging in by business now, on revenue growth. Our US Consumer business saw accelerating growth versus prior across the year, growing 5% in Q1, 7% in Q2, 9% in Q3, and 11% in Q4. For the full year, US Consumer grew 8% to $148.8 million. Our other businesses, which include International, Care@Work and Marketplace grew 20% versus prior to $43.5 million for the year. Within that Care@Work continued as a source of strength.

For 2018, Care@Work grew 34% versus 2017 to $18 million and for Q4, it grew 48% versus prior to $5.6 million. Given the high rate of growth and the impact that a single big deal can have, we expect to continue to see some flux in the delta versus prior from one quarter to the next. In keeping with our normal cadence, I'll now provide a deeper dive on unit economics for the US Consumer business, focusing on full year 2018 versus 2017.

Overall, the ROI improved 36% from 4.7x for full year 2017 to 6.4x for full year 2018. This was driven by a number of factors. Length of Paid Time or LOPT increased 6% from 14 months in 2017 to 14.8 months in 2018. As a reminder, at the start of each year, we typically take the opportunity to expand the observation window, to give better visibility to the long tail.

This is one benefit of our Care 3.0 focus on driving long-term improvements in member engagement, through our product investments and a mix shift toward longer duration subscription packages. We have also seen better rollover attention earlier tenure levels. As we've described the mix shift led to a natural decline in ARPU given that longer duration packages offered lower monthly prices. From 2017 to 2018, ARPU fell 2.4% from $39.86 to $38.89. While this was a partial offset, the increase in LOPT drove a 3.4% increase in LTV from $461 in 2017 to $471 in 2018.

Cost per acquired customer decreased 25% from $97 in 2017 to $73 in 2018. This was the result of activities that Sheila referenced earlier, specifically continued progress with paid marketing optimization, product investment to drive conversion improvements and content and community improvements to drive unpaid acquisition. As a reminder, you can find additional detail, including the breakout between matching and payments, in our earnings results supplement, which we posted to the IR website this morning.

Now on to EBITDA , which was ahead of our expectations. We remain committed to driving shareholder value through profitable growth, with Q4 marking our 13th consecutive quarter of growing profitably. For Q4, EBITDA was $12.7 million for a margin of 26% compared to $11.4 million and 26% margin in Q4 of 2017. As a reminder, last quarter, we noted that we decided to make certain investments originally intended for Q3 and Q4 instead, to support key activities in the run-up to 2019. For the year, EBITDA was $32.2 million for a margin of 16.8% compared to $23.3 million for a 13.4% margin in 2017, representing a margin improvement versus prior of 340 basis points.

For 2018, net income attributable to common stockholders was $43.2 million, as compared to $6.9 million in 2017. For the fourth quarter, net income attributable to common stockholders was $41.3 million, as compared to $6.3 million in Q4 of 2017. Included in our GAAP net income was a one-time income tax benefit of approximately $45 million resulting from the reversal of the Company's valuation allowance against deferred tax assets, which had a flow through impact to EPS.

Now, moving onto the cost lines. Starting with gross margin, which was 78% for full year 2018, compared with 79% for 2017. As a reminder, Care@Work is our fastest growing business and it has a lower gross margin than the consumer business.

On to sales and marketing, we reduced sales and marketing by 7 percentage points, as a percent of revenue from 38% in 2017% to 31% in 2018. In 2018, R&D increased year-over-year, as a percent of revenue by 3 percentage points from 15% to 18%, as we continue to invest in innovation on both the B2C and B2B sides of the business. G&A, as a percent of revenue for 2018 was 23%, as compared to 20% last year. A key driver here was an evolution in our stock-based comp program. As I've discussed before, as we cycle past this, I do not expect stock-based comp to grow in 2019 at the rates we saw in 2018.

Moving now to EPS. For the year, GAAP EPS from continuing operations on a diluted basis was $1.29, up from $0.22 in 2017. For the quarter, GAAP EPS was $1.23 compared to $0.19 in the fourth quarter of 2017. As I mentioned in the context of net income, this includes the one-time benefit associated with the release of our valuation allowance.

Non-GAAP EPS for the year was $0.77, as compared to $0.69 in 2017. This improvement versus prior year was mainly the result of flow through from the EBITDA improvement versus prior, partially offset by cycling against the one-time benefit in 2017 associated with tax reform, that cycling effect was especially pronounced in Q4. Non-GAAP EPS in Q4 2018 was $0.26 cycling against $0.32 in Q4, 2017.

Regarding cash and short-term investments, we ended the year with a balance of $127.5 million, up $25.8 million from the end of 2017, and this includes the offset from about $10 million of cash that we spent on acquisitions in 2018.

Now, turning to guidance. I'll start with revenue. For full year revenue, we are guiding to $217 million to $221 million, up approximately 14% versus prior -- prior at the midpoint. This represents about 4 percentage points of acceleration relative to the 10% growth versus prior we saw in 2018. Given the cadence of our investments and the year-ago comps, we expect the revenue growth rate in 2019 to increase across the year beginning with 11% in Q1. We are guiding to Q1 revenue of $52.5 million to $52.8 million.

On EBITDA, we are guiding to $33 million to $35 million for the full year, yielding EBITDA margin of about 16% to the middle of the range. As we've described before, the efficiency of our model and the compelling unit economics, give us the flexibility to invest incrementally to drive long-term growth, while maintaining healthy margins.

As Sheila mentioned, the key areas of incremental investment in 2019 are as follows: one, expansion of our child care offerings through the integration of our tuck-ins; two, senior care market in which we expect to drive revenue efficiently with much of that revenue coming after 2019; three, Care@Work in support of continued healthy growth fueled by new clients and renewals; and four, operational excellence initiatives. These investments resulted in lower flow through from incremental revenue to incremental EBITDA for 2019 versus 2018, than we saw in 2018 versus 2017, which is consistent with how we frame the possible pathways from negative margins back in 2015 to our long-term EBIT target margin range, specifically that it wouldn't necessarily be a straight line.

We remain comfortable with the expectation we have shared that we will get to that range on the back of revenue growth with incremental revenue flowing through more significantly to incremental EBITDA, and that the expected return on the investments we're making now will help us to achieve that. The planned cadence of these investments drives the shape of the year on the EBITDA line. While we are guiding to roughly 16% EBITDA margin for the full year, we're expecting roughly 7% in Q1. Our Q1 guidance range is $3.7 million to $4 million.

For full year, non-GAAP EPS, we're guiding to $0.73 to $0.78. This is based on an expectation of about 41 million weighted average diluted shares outstanding. For the first quarter, we're guiding to non-GAAP EPS of approximately $0.08 with an expectation of roughly 40 million weighted average diluted shares outstanding. Finally, we expect to end 2019 with about $145 million in cash and short-term investments, driven primarily by EBITDA flow through and partially offset by outflows related to the Figure8 acquisition and earn outs from earlier acquisitions.

In 2018, we drove further profitable growth, while positioning ourselves for acceleration in 2019. We remain focused on key strategic initiatives on both the B2C and B2B sides of the business with the goal of providing a wide range of high quality care options for families and penetrating ever more of our large total addressable market.

With that, I'll open the call to your questions. Operator?

Questions and Answers:

Operator

Thank you. We will now be conducting a question-and-answer session. (Operator Instructions) Our first question today is coming from Jason Kreyer from Craig-Hallum. Your line is now live.

Jason Kreyer -- Craig-Hallum -- Analyst

Good morning. Thank you for taking my questions. Just wanted to start on Explore. So maybe you can give us just some insight into the progress of the integration there, the expected timeframe for the roll out of Explore. And then when you go to market with that product is this embedded within the subscription or you use (ph) this as more of a lead generator for customer acquisition and kind of what the goal of that driving better conversion down the road?

Sheila Lirio Marcelo -- Founder, Chairwoman & Chief Executive Officer

Sure, Jason. Yeah, we're super excited about Galore now called Care.com Explore, and we're actually integrating that with the coordination and communication tools with Figure8 that we're just announcing today. Our intent really is to integrate that as part of subscription overall and at the same time, also as potential lead generation because I think we can offer different versions of the products and feature sets, and so we're excited to do that. We're continuing to really sign up a bunch of different activity platforms and integrating them to use the SaaS tool of Care.com Explore and so we'll be announcing those soon, and with that continues to be an exciting investment opportunity.

Jason Kreyer -- Craig-Hallum -- Analyst

Okay. And then just one follow-up. The -- in Q4, we saw a more substantial pullback in direct marketing spend than we've seen in past quarters. Just wondering if you can chime (ph) in a little bit of a light on that, is that just based on seasonality? Is that driven by more efficiency in different channels like, any color would be great?

Michael Echenberg -- Chief Financial Officer

Yeah. Thanks, Jason. I'd say that with respect to sales and marketing, I think setting aside any fluctuations from one quarter to the next, the main focus today is around -- as we look ahead to 2019, the expectation that we'll be turning the dial back up on sales and marketing as we've described feeling good that on the back of the efficiency gains and the conversion improvements we can do that with an expected -- an expectation of efficiency. And in particular, we're looking forward to continuing to build on the momentum, we're seeing in senior care. And so as a general matter, Q4 was a little different from Q3 with respect to the delta versus prior. But the general story that we saw in 2018 remain consistent, which was continuing to optimize for efficiency. And then in 2019, as we talk about acceleration that sales and marketing line will go back a bit in the other direction.

Jason Kreyer -- Craig-Hallum -- Analyst

Got it. Thank you.

Operator

Thank you. Our next question today is coming from Marvin Fong from BTIG. Your line is now live.

Marvin Fong -- BTIG -- Analyst

Hi, thanks for taking my question. Just thought I'd start with Care@Work and the new clients that you've onboarded recently the front -- the ones with lots of frontline employees. Have you noticed anything different about these -- your experience with these employees in terms of their uptake of the product as compared to some of your past covered families given there is a little bit different type of employee set?

Sheila Lirio Marcelo -- Founder, Chairwoman & Chief Executive Officer

What's interesting is because we are the leading brand and platform on the consumer side for care, our ability to actually service across the country given the ubiquity of the service is allowing us to really leverage our B2C platform to service B2B and that was always the vision and the design since founding. So we continue to be excited. And the focus of consumer to be mass market allows us to really lend itself for the product on the B2B side.

Marvin Fong -- BTIG -- Analyst

Okay, great. Thank you. And just one follow-up, just on senior care. Can you give us any broader picture about how much faster it's growing than say the child care business. And just sort of any opportunity to expand the product set there or it's something more to drive the adoption of in-home senior care? Thanks.

Sheila Lirio Marcelo -- Founder, Chairwoman & Chief Executive Officer

Yeah. We haven't -- we haven't actually broken it out other than in our prepared remarks that Michael and I shared that. It is growing fast -- it is the fastest growing vertical. And as of '17, '18, we started verticalizing enrollment and the overall experience and that we timed with the test spending on senior care ads (ph) across our different acquisition channels, and we saw real productive unit economics and CAC that was comparable to child care. So we continue to be excited. Michael just answered another question around, our investing more there because the test spending, plus investments we've made in the product, we really feel is sort of a strong indicator to continue to invest given the strength of the unit economics of this vertical.

Michael Echenberg -- Chief Financial Officer

The only thing I might add to that is to say that while we expect to drive incremental sign ups through this vertical, we also like what we see with respect to families and caregivers already on the platform, who might have joined us for child care moving into this vertical as well. It fits nicely with the original brand thesis that if we build the trust based relationship with mom with respect to one set of care needs, she will come to trust us more broadly for her other care needs too.

Sheila Lirio Marcelo -- Founder, Chairwoman & Chief Executive Officer

And it's the demographic trends with regards to the sandwich generation, where I believe half of 40-year-old to 50-year-old are -- or between 40-year-old and 60-year-olds are already sandwiched between child care and senior care and trying to find in-home solutions, there is a natural overlap between the child care and senior care offering that we have.

Marvin Fong -- BTIG -- Analyst

Great. Thank you. If I could just sneak one more in. On Care.com Explore, I understand what you're saying about integrating it with the subscription model. Is there any revenue stream that you collect from the service provider? Or is it just going to be just integrate with the subscription and that will be the main source of revenue? Thanks.

Sheila Lirio Marcelo -- Founder, Chairwoman & Chief Executive Officer

Yes, there is a revenue stream from the different service providers. So there will be an SMB portion of the business, as well as consumer revenue from the after school.

Marvin Fong -- BTIG -- Analyst

Okay. Thank you. Sorry. Thank you very much. Appreciate it.

Operator

(Operator Instructions) Our next question is coming from Dillon Heslin from ROTH Capital Partners. Your line is now live.

Dillon Heslin -- ROTH Capital Partners -- Analyst

Hi, thanks for taking my questions. Quickly on some of the senior marketing initiatives, could you talk about how senior care marketing might differ from some of the child care efforts you've taken in the past, and are you primarily more focused on targeting your current members or a mix of current and new members? And then as a follow-up, are you able to sort of quantify the LOPT impact that's obviously gone up, how it could have been impacted by the acquisitions, so sort of like an organic number versus the incremental impacts from -- from the two acquisitions you made? Thank you.

Sheila Lirio Marcelo -- Founder, Chairwoman & Chief Executive Officer

Sure. Let me start with senior care and I'll turn the LOPT over to Michael, Dillon. So on the senior care side, in terms of overall marketing channels, we're actually targeting as Michael pointed out both our existing members because there is a natural overlap. Now that we're 12-years-old and also the brand vision has always been around child care and senior care, there is a natural, I think uptake that we're seeing with regards to senior care vertical, but as well as new because of the phenomena of families starting to struggle with this child care and senior care being sandwich. So I think the opportunities for us continue to be both and that they're exciting, and it's starting to show in the numbers, as I've indicated in our prepared remarks. I'm turning it over to LOPT.

Michael Echenberg -- Chief Financial Officer

Yeah. It's a great question with respect to the impact of the acquisitions on LOPT because as I'm sure, you're assuming in your question, these product tuck-ins are around increasing engagement and you'd expect over time for that to contribute to LOPT. I'd say a couple of things, one is, it would be a little bit early to see them adding meaningfully to the long tail just yet given how recently we acquired them. And then it hasn't been our practice to break apart the LOPT curves by vertical or by part of the -- part of the -- the offering. And so, obviously, we reserve the right to evolve our KPIs over time, but in any event, it would be early to see that in the numbers that we share today.

Dillon Heslin -- ROTH Capital Partners -- Analyst

Great. Thank you.

Operator

Thank you. We reached the end of our question-and-answer session. I'd like to turn the floor back over to management for any further or closing comments.

Michael Echenberg -- Chief Financial Officer

Thank you for joining us today.

Operator

Thank you. That does conclude today's teleconference. You may disconnect your lines, at this time, and have a wonderful day. We thank you for your participation today.

Duration: 38 minutes

Call participants:

Mike Goss -- Vice President of Finance

Sheila Lirio Marcelo -- Founder, Chairwoman & Chief Executive Officer

Michael Echenberg -- Chief Financial Officer

Jason Kreyer -- Craig-Hallum -- Analyst

Marvin Fong -- BTIG -- Analyst

Dillon Heslin -- ROTH Capital Partners -- Analyst

More CRCM analysis

Transcript powered by AlphaStreet

This article is a transcript of this conference call produced for The Motley Fool. While we strive for our Foolish Best, there may be errors, omissions, or inaccuracies in this transcript. As with all our articles, The Motley Fool does not assume any responsibility for your use of this content, and we strongly encourage you to do your own research, including listening to the call yourself and reading the company's SEC filings. Please see our Terms and Conditions for additional details, including our Obligatory Capitalized Disclaimers of Liability.

Wednesday, March 6, 2019

Ashoka Buildcon rallies 7% after JV emerges as lowest bidder for railway project

Ashoka Buildcon shares gained 7 percent intraday on Tuesday after the joint venture company emerged as lowest bidder for railway project by Rail Vikas Nigam.

The company has submitted bid to Rail Vikas Nigam Limited in Joint Venture with Stroytech Services LLC, wherein the company is a lead member, for the project.

The project includes construction of roadbed, minor bridges, supply of ballast, installation of track (excluding supply of rails & PSC sleepers & thick web switches), electrical (railway electrification and general electrification), signalling and telecommunication works for doubling of track between Kakrala halt (excluding) and Hadiaya (including) in Ambala Division of Northern Railway, Punjab.

"The company has emerged as the lowest bidder (L-1) for Package 2, the quoted value of which is Rs 443.23 crore, with a completion period of 36 months for package," Ashoka Buildcon said.

At 13:40 hours IST, the stock was quoting at Rs 129.30, up Rs 8.15, or 6.73 percent on the BSE. First Published on Mar 5, 2019 01:40 pm

Tuesday, March 5, 2019

Why Geron Skyrocketed 27% in February

What happened

After it announced on Jan. 31 that a former, key Johnson & Johnson (NYSE:JNJ) researcher was becoming its chief medical officer, shares in Geron (NASDAQ:GERN) rallied 27% in February, according to S&P Global Market Intelligence.

So what

J&J disappointed Geron shareholders last fall when it discontinued codevelopment of Geron's imetelstat, a myelodysplastic syndromes (MDS) and myelofibrosis therapy.

A man in a suit shouts into a megaphone in front of wall displaying an ascending stock price chart.

Image source: Getty Images.

If J&J had agreed to advance imetelstat into trials that could support Food and Drug Administration (FDA) approval, Geron could've received hundreds of millions of dollars in additional milestone revenue, plus potential royalties. However, limited efficacy in myelofibrosis and unconvincing data in MDS weren't enough to maintain J&J's interest.

J&J has given up on imetelstat, but one of its key researchers hasn't. On Jan. 31, the researcher who formerly led imetelstat development at J&J, Aleksandra Rizo, signed on as Geron's chief medical officer following a brief stint at Celgene. Rizo will now be in charge of executing Geron's soon-to-start phase 3 trial program in MDS, and of determining imetelstat's fate in myelofibrosis.

Now what

Imetelstat failed to reduce spleen volume in myelofibrosis patients by the targeted amount in trials, forcing future development in that indication to focus on overall survival. Overall survival is a tougher bar to clear, so Geron is debating its options in myelofibrosis to conserve cash.

Now it's focusing on MDS, where it believes imetelstat has a clearer pathway to succeeding. A phase 3 study in that indication is scheduled to begin this year. Investors might want to keep some optimism in check, though. R&D expenses are heading higher, and that could mean Geron faces a cash crunch next year. For that reason, it will be important to keep tabs on cash burn throughout 2019.

Monday, March 4, 2019

Top Casino Stocks For 2019

tags:SAN,SYKE,NGD,PEO,SMCI, &l;p&g;&l;img class=&q;dam-image getty size-large wp-image-161151943&q; src=&q;https://specials-images.forbesimg.com/dam/imageserve/161151943/960x0.jpg?fit=scale&q; data-height=&q;627&q; data-width=&q;960&q;&g; Cripple Creek, a former gold-mining boom town 44 miles southwest of Colorado Springs, is now home to 13 casinos after Colorado voters allowed the town to re-establish gambling in 1991. This July casinos will be allowed to stay open 24/7 and expand gaming with $100 bets and the addition of craps and roulette. Karl Gehring/The Denver Post (Photo By Karl Gehring/The Denver Post via Getty Images)

&l;em&g;&a;ldquo;Are ya feelin&a;rsquo; lucky?&a;rdquo; &l;/em&g;

When it comes to my money, I&a;rsquo;m not a gambler - especially with my investments. Continually inspired by Benjamin Graham for his value investing approach, my aim for Real Estate Investment Trust (REIT) investing is simply to be... intelligent.

As editor of &l;em&g;&l;a href=&q;https://esp.forbes.com/subscribe?PC=VE&q; target=&q;_blank&q;&g;Forbes Real Estate Investor&l;/a&g;,&l;/em&g; I rate REITs and write about &a;lsquo;em (say that three times fast).

Top Casino Stocks For 2019: Banco Santander, S.A.(SAN)

Advisors' Opinion:
  • [By Shane Hupp]

    Bank of America set a €95.00 ($110.47) price objective on Sanofi (EPA:SAN) in a report released on Monday. The brokerage currently has a buy rating on the stock.

  • [By Ethan Ryder]

    Banco Santander, S.A. (NYSE:SAN) shares gapped down prior to trading on Monday . The stock had previously closed at $5.14, but opened at $4.98. Banco Santander shares last traded at $4.94, with a volume of 436686 shares.

  • [By Ethan Ryder]

    Shares of Sanofi SA (EPA:SAN) have received an average rating of “Hold” from the nineteen brokerages that are currently covering the company, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, ten have given a hold rating and seven have issued a buy rating on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is €79.21 ($92.11).

  • [By Shane Hupp]

    Banco Santander (NYSE:SAN) and Societe Generale (OTCMKTS:SCGLY) are both large-cap finance companies, but which is the superior stock? We will compare the two companies based on the strength of their dividends, valuation, analyst recommendations, profitability, institutional ownership, earnings and risk.

Top Casino Stocks For 2019: Sykes Enterprises, Incorporated(SYKE)

Advisors' Opinion:
  • [By Stephan Byrd]

    Shares of Sykes Enterprises (NASDAQ:SYKE) have been given an average recommendation of “Hold” by the seven research firms that are presently covering the stock, Marketbeat reports. Two research analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The average twelve-month price objective among brokerages that have updated their coverage on the stock in the last year is $31.00.

  • [By Ethan Ryder]

    Barrington Research reiterated their hold rating on shares of Sykes Enterprises (NASDAQ:SYKE) in a research note issued to investors on Thursday morning.

  • [By Logan Wallace]

    Wells Fargo & Company MN boosted its stake in Sykes Enterprises, Incorporated (NASDAQ:SYKE) by 0.5% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,209,615 shares of the information technology services provider’s stock after buying an additional 5,839 shares during the quarter. Wells Fargo & Company MN owned approximately 2.83% of Sykes Enterprises worth $34,813,000 at the end of the most recent reporting period.

  • [By Max Byerly]

    Raymond James & Associates boosted its position in shares of Sykes Enterprises, Incorporated (NASDAQ:SYKE) by 29.5% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 67,982 shares of the information technology services provider’s stock after acquiring an additional 15,471 shares during the period. Raymond James & Associates owned about 0.16% of Sykes Enterprises worth $1,957,000 as of its most recent SEC filing.

Top Casino Stocks For 2019: NEW GOLD INC.(NGD)

Advisors' Opinion:
  • [By Paul Ausick]

    New Gold Inc. (NYSEAMERICAN: NGD) dropped about 2.9% Monday to post a new 52-week low of $2.35. Shares closed at $2.42 on Friday and the stock’s 52-week high is $4.25. Volume was about 10% below the daily average of around 5.8 million shares. The gold mining company had no news.

  • [By Lisa Levin] Gainers ARMO BioSciences, Inc. (NASDAQ: ARMO) shares rose 67.5 percent to $49.96 in pre-market trading after Eli Lilly and Company (NYSE: LLY) announced plans to acquire ARMO BioSciences for $50 per share. Turtle Beach Corporation (NASDAQ: HEAR) rose 62.8 percent to $11.30 in pre-market trading after the company reported Q1 results and raised its FY18 outlook. vTv Therapeutics Inc. (NASDAQ: VTVT) rose 23.4 percent to $2.11 in pre-market trading following announcement that the company will pre-specify new subgroup with the FDA and report Phase 3 Part B results in June. Resonant Inc. (NASDAQ: RESN) rose 19.1 percent to $5.00 in pre-market trading after reporting Q1 results. RXi Pharmaceuticals Corporation (NASDAQ: RXII) rose 17.7 percent to $2.39 in pre-market trading following Q1 results. Clean Energy Fuels Corp. (NASDAQ: CLNE) rose 15.2 percent to $2.20 in pre-market trading after French company Total announced plans to acquire 25 percent stake in Clean Energy Fuels for $83.4 million. Everspin Technologies, Inc. (NASDAQ: MRAM) rose 14.6 percent to $8.50 in pre-market trading after the company reported strong results for its first quarter. Carvana Co. (NYSE: CVNA) shares rose 11 percent to $27.50 in pre-market trading after reporting upbeat Q1 sales. Sunrun Inc. (NASDAQ: RUN) rose 8.9 percent to $10.70 in pre-market trading following upbeat quarterly earnings. MediciNova, Inc. (NASDAQ: MNOV) rose 8.1 percent to $11.35 in pre-market trading after the company announced opening of Investigational New Drug Application for MN-166 (ibudilast) in glioblastoma. New Gold Inc. (NYSE: NGD) shares rose 7.7 percent to $2.65 in pre-market trading after the company reported that its President and CEO Hannes Portmann left the company. The company named Raymond Threlkeld as successor. Otter Tail Corporation (NASDAQ: OTTR) shares rose 7.4 percent to $46.60 in the pre-market trading session. Himax Technologies, Inc. (NASDAQ: HIMX) shares rose
  • [By Lisa Levin]

    Check out these big penny stock gainers and losers

    Losers Teradyne, Inc. (NYSE: TER) fell 10.8 percent to $37.02 in pre-market trading after the company issued downbeat Q2 guidance. Edwards Lifesciences Corporation (NYSE: EW) fell 9.2 percent to $122.29 in pre-market trading. Edwards Lifesciences reported better-than-expected results for its first quarter, but issued weak earnings guidance for the second quarter. New Gold Inc. (NYSE: NGD) fell 8.8 percent to $2.30 in pre-market trading after rising 4.13 percent on Tuesday. Gold Fields Limited (ADR) (NYSE: GFI) fell 8.6 percent to $3.61 in pre-market trading. Natus Medical Incorporated (NASDAQ: BABY) fell 8.2 percent to $32.95 in pre-market trading after the company issued weak forecast for the second quarter. Atossa Genetics Inc. (NASDAQ: ATOS) shares fell 7.9 percent to $3.50 in pre-market trading after climbing 27.09 percent on Tuesday. Bright Scholar Education Holdings Limited (NYSE: BEDU) shares fell 6.7 percent to $13.58 in pre-market trading after reporting Q1 results. Sangamo Therapeutics Inc (NASDAQ: SGMO) fell 5.9 percent to $16.75 in pre-market trading following announcement of a $200 million common stock offering. Foresight Autonomous Holdings Ltd (NASDAQ: FRSX) shares fell 5.7 percent to $3.29 in pre-market trading after declining 3.32 percent on Tuesday. Euronav NV (NYSE: EURN) fell 4.8 percent to $8.40 in pre-market trading. Limelight Networks, Inc. (NASDAQ: LLNW) shares fell 4.3 percent to $4.69 in pre-market trading. Gaming and Leisure Properties Inc (NASDAQ: GLPI) shares fell 4.1 percent to $32.92 in pre-market trading after the company issued downbeat quarterly results and reported the retirement of CFO William Clifford
  • [By Stephan Byrd]

    JPMorgan Chase & Co. downgraded shares of New Gold (NYSEAMERICAN:NGD) from a neutral rating to an underweight rating in a research report released on Wednesday, The Fly reports.

  • [By Travis Hoium]

    Shares of miner New Gold Inc. (NYSEMKT:NGD) jumped as much as 19.4% in trading early Wednesday after the company announced a leadership change. Shares were hitting their high at 11:05 a.m. EDT and seemed to be gaining momentum.

  • [By Paul Ausick]

    New Gold Inc. (NYSEAMERICAN: NGD) dropped about 3.8% Thursday to post a new 52-week low of $2.28. Shares closed at $2.37 on Wednesday and the stock’s 52-week high is $4.25. Volume was about 15% below the daily average of around 5.9 million shares. The company had no specific news.

Top Casino Stocks For 2019: Petroleum Resources Corporation(PEO)

Advisors' Opinion:
  • [By Shane Hupp]

    Press coverage about Adams Natural Resources Fund (NYSE:PEO) has trended somewhat negative recently, Accern reports. The research group identifies positive and negative news coverage by monitoring more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Adams Natural Resources Fund earned a coverage optimism score of -0.09 on Accern’s scale. Accern also assigned news articles about the financial services provider an impact score of 48.0521373671292 out of 100, meaning that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the immediate future.

Top Casino Stocks For 2019: Super Micro Computer, Inc.(SMCI)

Advisors' Opinion:
  • [By Stephan Byrd]

    BidaskClub upgraded shares of Super Micro Computer (NASDAQ:SMCI) from a sell rating to a hold rating in a research note published on Friday.

    A number of other equities research analysts have also recently commented on the stock. Zacks Investment Research cut shares of Super Micro Computer from a strong-buy rating to a hold rating in a research note on Thursday, April 5th. Maxim Group increased their price objective on shares of Super Micro Computer from $45.00 to $50.00 and gave the company a buy rating in a research note on Wednesday, January 31st. Nine investment analysts have rated the stock with a hold rating and one has given a buy rating to the company. The stock has an average rating of Hold and a consensus target price of $28.14.

  • [By Evan Niu, CFA]

    Shares of Super Micro Computer (NASDAQ:SMCI) have gotten completely destroyed today, down by 43% as of 2:20 p.m. EDT, after Bloomberg published a bombshell report alleging that the company's server motherboards had been subject to a malicious hardware attack. The Chinese government is alleged to have installed a malicious chip used for spying purposes.

  • [By Paul Ausick]

    Super Micro Computer Inc. (NASDAQ: SMCI) traded down about 22.6% Wednesday to set a new 52-week low of $14.20. Shares closed at $18.35 on Tuesday, and the 52-week high is $27.90. Volume was about 35 times the daily average of around 380,000. The company’s stock will be delisted from Nasdaq for failure to meet SEC filing deadlines.

  • [By Lisa Levin] Gainers Biostar Pharmaceuticals, Inc. (NASDAQ: BSPM) shares jumped 29.86 percent to close at $2.87 on Friday. Commercial Vehicle Group, Inc. (NASDAQ: CVGI) shares gained 28.87 percent to close at $8.75 after reporting upbeat Q1 earnings. Mexco Energy Corporation (NYSE: MXC) gained 27.02 percent to close at $5.4744. Carbon Black, Inc. (NASDAQ: CBLK) climbed 26 percent to close at $23.94. Carbon Black priced its IPO at $19 per share. Portola Pharmaceuticals, Inc. (NASDAQ: PTLA) rose 25.64 percent to close at $42.44 after the FDA approved the company's Andexxa, the only antidote indicated for patients treated with rivaroxaban and apixaban. Natural Grocers by Vitamin Cottage, Inc. (NYSE: NGVC) rose 23.19 percent to close at $8.50 after reporting Q2 results. California Resources Corporation (NYSE: CRC) shares gained 22.45 percent to close at $31.58 following upbeat Q1 earnings. Atomera Incorporated (NASDAQ: ATOM) gained 22.31 percent to close at $6.25 after reporting Q1 results. Medifast, Inc. (NYSE: MED) shares jumped 22.27 percent to close at $121.46 after the company reported strong Q1 results and raised its FY18 guidance. Jerash Holdings (US), Inc. (NASDAQ: JRSH) gained 20.86 percent to close at $8.46. Pandora Media, Inc. (NYSE: P) rose 19.83 percent to close at $6.89 after reporting strong quarterly results. Shake Shack Inc (NYSE: SHAK) rose 18.01 percent to close at $55.95 on Friday after the company reported upbeat results for its first quarter and raised its FY18 guidance. Super Micro Computer, Inc. (NASDAQ: SMCI) rose 17.73 percent to close at $21.25 after reporting strong preliminary results for the third quarter. Schmitt Industries, Inc. (NASDAQ: SMIT) rose 17.41 percent to close at $2.36. Titan International, Inc. (NYSE: TWI) shares gained 16.78 percent to close at $12.25 following Q1 earnings. Integer Holdings Corporation (NYSE: ITGR) shares rose 14.23 percent to close at $63.40 following Q1 result
  • [By Evan Niu, CFA]

    Shares of Super Micro Computer (NASDAQ:SMCI) have plunged today, down by 9% as of 11:45 a.m. EDT, after the company reported preliminary fiscal fourth-quarter results. Super Micro also confirmed it will be delisted soon.